• Ocular Therapeutix will participate in Clinical Trials at the Summit 2026 in Las Vegas on June 12-13, 2026.
• Agenda centers on OTX-TKI, including an overview of the science plus Phase 3 SOL-1 efficacy and safety in neovascular AMD.
• Company leadership will also join fireside chats and a panel discussion on bringing novel treatments to market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040700PRIMZONEFULLFEED9731641) on June 04, 2026, and is solely responsible for the information contained therein.